Bouras Irene, Mingo Olivia
University College London Hospital, London NW1 2BU.
Br J Hosp Med (Lond). 2010 Jan;71(1):57. doi: 10.12968/hmed.2010.71.1.45980.
Cell salvage, the process whereby blood is suctioned from the surgical site then filtered, centrifuged and washed before being transfused, was first developed in 1974. Since then it has become a widely used technique which reduces the need for allogenic blood transfusion. Cell salvage was initially considered to be contraindicated in obstetrics, because of the risk of amniotic fluid emboli, in potentially 'dirty' surgical sites and in oncological surgery because of concerns about re-transfusion of malignant cells. However, cell salvage is now routinely used in obstetrics, particularly in massive haemorrhage, and in elective bowel resection. The potential use of cell salvage in oncological surgery has been highlighted following the National Institute for Health and Clinical Excellence (NICE, 2008) guidance sanctioning (although not specifically recommending) cell salvage during radical prostatectomy and cystectomy. This leads to the question of whether cell salvage is safe to use in these and other types of oncological surgery.
细胞回收是指将手术部位的血液吸出，经过过滤、离心和清洗后再进行输血的过程，该技术于1974年首次研发。从那时起，它已成为一种广泛应用的技术，减少了异体输血的需求。细胞回收最初被认为在产科是禁忌的，因为存在羊水栓塞的风险，在潜在的“污染”手术部位以及肿瘤手术中，由于担心恶性细胞的回输。然而，细胞回收现在在产科常规使用，特别是在大出血时，以及在择期肠道切除术中。在英国国家卫生与临床优化研究所（NICE，2008年）发布指导意见批准（尽管未特别推荐）在根治性前列腺切除术和膀胱切除术中使用细胞回收后，细胞回收在肿瘤手术中的潜在应用受到了关注。这就引出了一个问题，即在这些以及其他类型的肿瘤手术中使用细胞回收是否安全。
